{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:15:16Z","timestamp":1791951316659,"version":"4.3.4"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"collaborative Trajectory Analysis Project"},{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>This study examined functional trajectories of subjects during the transition phase between ambulatory and non-ambulatory Duchenne muscular dystrophy (DMD) to inform clinical trial designs for new therapeutics. Ambulatory, pulmonary, and upper limb function leading up to loss of ambulation (LoA) and non-ambulatory measures following LoA were quantified; time ordering of pulmonary and upper limb milestones relative to LoA were determined; and the 10-second time threshold for 10-meter walk\/run (10MWR) as a marker of approaching LOA was explored. Included in this analysis were 51 subjects aged between 7 and 18 years who experienced LoA during follow-up in the PRO-DMD-01 natural history study. Mean age at LoA was 12.7 (7.1\u201318.6) years. Mean annual rates of decline in forced vital capacity (FVC) &lt;80%-predicted and performance of upper limb (PUL) 1.2 total score were smaller before than after LoA, but not significantly (FVC %-predicted: 5.6% vs. 10.1%, <jats:italic>p<\/jats:italic> = 0.21; PUL 1.2 total score: 2.3 vs. 3.8 units, <jats:italic>p<\/jats:italic> = 0.20). More than half of patients experienced clinically significant deficits in FVC %-predicted and PUL 1.2 before experiencing LoA. Among subjects with baseline 10MWR &gt;10 s, those with &lt;1 year to LoA had similar mean ages but significantly worse mean ambulatory function at baseline compared to those with \u22651 year to LoA. Enriching DMD clinical trials for patients with declining pulmonary or upper limb function is achievable without restricting enrollment to non-ambulatory patients. The sequencing of LoA and initial deficits in pulmonary and upper limb function varied across patients and highlights the potential for composite outcomes or multi-outcome trial designs to assess disease-modifying therapies more comprehensively.<\/jats:p>","DOI":"10.1371\/journal.pone.0304099","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T17:31:25Z","timestamp":1717435885000},"page":"e0304099","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Functional trajectories before and after loss of ambulation in Duchenne muscular dystrophy and implications for clinical trials"],"prefix":"10.1371","volume":"19","author":[{"given":"Craig M.","family":"McDonald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4067-8962","authenticated-orcid":true,"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5892-5143","authenticated-orcid":true,"given":"Erik H.","family":"Niks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Fillbrunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Sajeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahima","family":"Dieye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Goemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Investigators from the PRO-DMD-01 Study, Collaborative Trajectory Analysis Project (cTAP)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"issue":"1","key":"pone.0304099.ref001","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global Epidemiology of Duchenne muscular dystrophy: An updated systematic review and meta-analysis.","volume":"15","author":"S Crisafulli","year":"2020","journal-title":"Orphanet J Rare Dis."},{"issue":"1","key":"pone.0304099.ref002","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13018-022-02996-8","article-title":"Global prevalence of Duchenne and Becker muscular dystrophy: a systematic review and meta-analysis.","volume":"17","author":"N Salari","year":"2022","journal-title":"J Orthop Surg Res."},{"issue":"10213","key":"pone.0304099.ref003","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","article-title":"Muscular dystrophies.","volume":"394","author":"E Mercuri","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"pone.0304099.ref004","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1212\/WNL.39.4.475","article-title":"Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy","volume":"39","author":"MH Brooke","year":"1989","journal-title":"Neurology"},{"issue":"10119","key":"pone.0304099.ref005","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study","volume":"391","author":"CM McDonald","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"pone.0304099.ref006","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management.","volume":"17","author":"DJ Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"issue":"4","key":"pone.0304099.ref007","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"DJ Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"issue":"5","key":"pone.0304099.ref008","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1474-4422(18)30026-7","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan","volume":"17","author":"DJ Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"issue":"1","key":"pone.0304099.ref009","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy.","volume":"7","author":"D Duan","year":"2021","journal-title":"Nat Rev Dis Primers."},{"key":"pone.0304099.ref010","doi-asserted-by":"crossref","first-page":"689533","DOI":"10.3389\/fcell.2021.689533","article-title":"Current Pharmacological Strategies for Duchenne Muscular Dystrophy.","volume":"9","author":"S Yao","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"pone.0304099.ref011","doi-asserted-by":"crossref","first-page":"735912","DOI":"10.3389\/fphar.2021.735912","article-title":"Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy.","volume":"12","author":"T Markati","year":"2021","journal-title":"Front Pharmacol."},{"issue":"2","key":"pone.0304099.ref012","first-page":"149","article-title":"The Northstar Ambulatory Assessment in duchenne muscular dystrophy: Considerations for the design of clinical trials","volume":"87","author":"V Ricotti","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"pone.0304099.ref013","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/psp4.12753","article-title":"Development of a model\u2010based clinical trial simulation platform to optimize the design of clinical trials for Duchenne Muscular Dystrophy","volume":"11","author":"K Lingineni","year":"2022","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"4","key":"pone.0304099.ref014","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00246-021-02797-6","article-title":"Diversity of Dystrophin Gene Mutations and Disease Progression in a Contemporary Cohort of Duchenne Muscular Dystrophy.","volume":"43","author":"KE Gambetta","year":"2022","journal-title":"Pediatr Cardiol"},{"issue":"10","key":"pone.0304099.ref015","doi-asserted-by":"crossref","first-page":"e0164684","DOI":"10.1371\/journal.pone.0164684","article-title":"Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy.","volume":"11","author":"Collaborative Trajectory Analysis Project (cTAP)","year":"2016","journal-title":"PLoS One."},{"issue":"9","key":"pone.0304099.ref016","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.nmd.2016.05.016","article-title":"Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy","volume":"26","author":"DMD Italian Group","year":"2016","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"pone.0304099.ref017","doi-asserted-by":"crossref","first-page":"e0221097","DOI":"10.1371\/journal.pone.0221097","article-title":"Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy.","volume":"14","author":"F Muntoni","year":"2019","journal-title":"PLoS One."},{"issue":"10101","key":"pone.0304099.ref018","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation duchenne muscular dystrophy (act DMD): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"390","author":"CM McDonald","year":"2017","journal-title":"Lancet"},{"issue":"17","key":"pone.0304099.ref019","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1212\/WNL.0000000000004570","article-title":"A phase 3 randomized placebo-controlled trial of Tadalafil for duchenne muscular dystrophy","volume":"89","author":"RG Victor","year":"2017","journal-title":"Neurology"},{"issue":"6","key":"pone.0304099.ref020","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.nmd.2020.05.002","article-title":"Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne Muscular Dystrophy.","volume":"30","author":"KR Wagner","year":"2020","journal-title":"Neuromuscular Disord"},{"issue":"5","key":"pone.0304099.ref021","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3233\/JND-210689","article-title":"A randomized, double-blind, placebo-controlled, Global Phase 3 study of edasalonexent in pediatric patients with Duchenne muscular dystrophy: Results of the POLARISDMD trial.","volume":"8","author":"RS Finkel","year":"2021","journal-title":"J Neuromuscul Dis."},{"issue":"8","key":"pone.0304099.ref022","doi-asserted-by":"crossref","first-page":"e866","DOI":"10.1212\/WNL.0000000000006950","article-title":"Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial","volume":"92","author":"M Taylor","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"pone.0304099.ref023","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3233\/JND-170245","article-title":"Efficacy of Idebenone to Preserve Respiratory Function above Clinically Meaningful Thresholds for Forced Vital Capacity (FVC) in Patients with Duchenne Muscular Dystrophy.","volume":"4","author":"DELOS Study Group","year":"2017","journal-title":"J Neuromuscul Dis."},{"issue":"11","key":"pone.0304099.ref024","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.nmd.2018.07.004","article-title":"Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoids","volume":"28","author":"CM McDonald","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"10329","key":"pone.0304099.ref025","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(22)00012-5","article-title":"Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.","volume":"399","author":"CM McDonald","year":"2022","journal-title":"Lancet"},{"key":"pone.0304099.ref026","unstructured":"Home Page [Internet]. CureDuchenne. 2022 [cited 2022 Oct 21]. Available from: https:\/\/cureduchenne.org\/"},{"issue":"3","key":"pone.0304099.ref027","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pri.221","article-title":"Validity of the EK scale: a functional assessment of non\u2010ambulatory individuals with Duchenne muscular dystrophy or spinal muscular atrophy","volume":"6","author":"Birgit Steffensen","year":"2001","journal-title":"Physiotherapy research international"},{"issue":"9","key":"pone.0304099.ref028","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.nmd.2012.06.245","article-title":"\"SP 6 Exploratory Rasch analysis of the EK2 scale used in a population of Duchenne muscular dystrophy (DMD).\"","volume":"22","author":"A. G. Mayhew","year":"2012","journal-title":"Neuromuscular Disorders"},{"issue":"11","key":"pone.0304099.ref029","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1164\/rccm.201710-1981ST","article-title":"Recommendations for a standardized pulmonary function report. an official American Thoracic Society Technical Statement","volume":"196","author":"BH Culver","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"pone.0304099.ref030","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","article-title":"Spirometric reference values from a sample of the general U.S. population","volume":"159","author":"JL Hankinson","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"pone.0304099.ref031","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.nmd.2012.06.006","article-title":"International Workshop on assessment of upper limb function in Duchenne muscular dystrophy","volume":"22","author":"E Mercuri","year":"2012","journal-title":"Neuromuscul Disord"},{"issue":"11","key":"pone.0304099.ref032","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/dmcn.12213","article-title":"Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy","volume":"55","author":"A Mayhew","year":"2013","journal-title":"Dev Med Child Neurol"},{"issue":"9","key":"pone.0304099.ref033","doi-asserted-by":"crossref","first-page":"e0239064","DOI":"10.1371\/journal.pone.0239064","article-title":"Test-retest reliability of the Performance of Upper Limb (PUL) module for muscular dystrophy patients.","volume":"15","author":"M Gandolla","year":"2020","journal-title":"PLoS One"},{"issue":"5","key":"pone.0304099.ref034","first-page":"359","article-title":"A stepwise approach to the interpretation of pulmonary function tests.","volume":"89","author":"JD Johnson","year":"2014","journal-title":"Am Fam Physician"},{"issue":"1","key":"pone.0304099.ref035","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review.","volume":"12","author":"S Ryder","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"pone.0304099.ref036","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/dmcn.15176","article-title":"Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy.","volume":"64","author":"AA Zambon","year":"2022","journal-title":"Dev Med Child Neurol."},{"key":"pone.0304099.ref037","volume-title":"R Foundation for statistical computing","author":"R Core Team","year":"2022"},{"issue":"2","key":"pone.0304099.ref038","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejpn.2011.07.001","article-title":"Motor and respiratory heterogeneity in Duchenne patients: implication for clinical trials.","volume":"16","author":"V Humbertclaude","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"issue":"5 Suppl","key":"pone.0304099.ref039","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1097\/00002060-199509001-00003","article-title":"Profiles of neuromuscular diseases. Duchenne muscular dystrophy","volume":"74","author":"CM McDonald","year":"1995","journal-title":"Am J Phys Med Rehabil"},{"issue":"3","key":"pone.0304099.ref040","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mus.23902","article-title":"The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study","volume":"48","author":"CM McDonald","year":"2013","journal-title":"Muscle Nerve"},{"issue":"6","key":"pone.0304099.ref041","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1469-8749.2011.03939.x","article-title":"Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy.","volume":"53","author":"North Star Clinical Network for Paediatric Neuromuscular Disease","year":"2011","journal-title":"Dev Med Child Neurol."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0304099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T17:32:04Z","timestamp":1717435924000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0304099"}},"subtitle":[],"editor":[{"given":"Atsushi","family":"Asakura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0304099","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]}}}